EUVIMEDEUVIMED entdecken
Open Access

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations

David J Einstein, Melissa L Abel iD, Jeanny B Aragon-Ching iD, Philip M Arlen, Karen A Autio iD, Marijo Bilusic iD, Michael A Carducci iD, Peter L Choyke, Deborah E Citrin iD, William D Figg iD, Julie N Graff iD, James L Gulley iD und 20 weitere

Journal of Clinical Oncology · 2025-12 · 43 (34) · 3672-3683

DOI: 10.1200/jco-25-01693 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025-12. Verfasst von David J Einstein und 31 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Recurrence, Local, Research Design, Clinical Trials as Topic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Biochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research inspired by ultrasensitive next-generation imaging. Most phase III trials in PCa have focused on metastatic disease, defined by conventional imaging. Despite the emergence of new imaging, clinical trial principles from metastatic studies will not optimize future BCR trials. METHODS A Working Group convened at the National Cancer Institute on November 13, 2024 (NCI BCR WG). Key areas of discussion included nomenclature, baseline criteria for data capture, imaging considerations, delineation of high-risk populations to be targeted for trial development, requirements of metastasis-directed therapy (MDT) or hormonal therapy, quality-of-life considerations, and potential study end points. RESULTS The NCI BCR WG defined the novel term “prostate-specific membrane antigen (PSMA)+BCR” to identify the emerging concept of recurrent PCa identifiable only on PSMA positron emission tomography (PET), overlapping with BCR and distinct from metastatic hormone-sensitive PCa as traditionally defined by conventional imaging. The WG suggested defining high-risk BCR with a prostate-specific antigen doubling time of ≤6 months, regardless of PET findings. The WG provided recommendations for baseline data capture and imaging requirements. Neither systemic therapy nor MDT were considered mandatory for control arms. The WG also discussed novel end points and quality-of-life metrics in this disease space. CONCLUSION These discussions should inform future clinical BCR trials in this distinct disease space relative to metastatic disease defined by conventional imaging. The NCI BCR WG strongly advocates that future trials explore deintensification of treatment to minimize toxicity in this relatively indolent disease state.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplasm Recurrence, LocalResearch DesignClinical Trials as TopicHumansMaleUnited StatesNational Cancer Institute (U.S.)Quality of LifeProstate-Specific Antigen

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, MA.
  • Center for Cancer Research, National Cancer Institute, Bethesda, MD.
  • Inova Schar Cancer Institute, Fairfax, VA.
  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • Division of Medical Oncology, University of Miami Miller School of Medicine, Miami, FL.
  • Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.

ORCID-Profile: Melissa L Abel, Jeanny B Aragon-Ching, Karen A Autio, Marijo Bilusic, Michael A Carducci, Deborah E Citrin, William D Figg, Julie N Graff, James L Gulley, Susan Halabi, Fatima Karzai, Liza Lindenberg, Mark C Markowski, Catherine H Marshall, Douglas G McNeel, Russell K Pachynski, Channing J Paller, Krishnan R Patel, Edwin M Posadas, Kenneth J Pienta, Meredith M Regan, Laura A Sena, Evan Y Yu, Phuoc T Tran, Ravi A Madan

Förderung

  • NCI NIH HHS

Zitieren

APA

Einstein, D. J., Abel, M. L., Aragon-Ching, J. B., Arlen, P. M., Autio, K. A., Bilusic, M., Carducci, M. A., Choyke, P. L., Citrin, D. E., Figg, W. D., Graff, J. N., Gulley, J. L., Halabi, S., Karzai, F., Lindenberg, L., Markowski, M. C., Marshall, C. H., McNeel, D. G., Mena, E., …, & Madan, R. A. (2025). National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations. Journal of Clinical Oncology, 43(34), 3672-3683. https://doi.org/10.1200/jco-25-01693

Vancouver

Einstein DJ, Abel ML, Aragon-Ching JB, Arlen PM, Autio KA, Bilusic M, et al. National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations. Journal of Clinical Oncology. 2025;43(34):3672-3683. doi:10.1200/jco-25-01693

BibTeX
@article{Einstein2025,
  author = {Einstein, David J and Abel, Melissa L and Aragon-Ching, Jeanny B and Arlen, Philip M and Autio, Karen A and Bilusic, Marijo and Carducci, Michael A and Choyke, Peter L and Citrin, Deborah E and Figg, William D and Graff, Julie N and Gulley, James L and Halabi, Susan and Karzai, Fatima and Lindenberg, Liza and Markowski, Mark C and Marshall, Catherine H and McNeel, Douglas G and Mena, Esther and Moon, Helen and Pachynski, Russell K and Paller, Channing J and Patel, Krishnan R and Posadas, Edwin M and Pienta, Kenneth J and Regan, Meredith M and Sena, Laura A and Walmsley, Charlotte S and Wei, Xiao X and Yu, Evan Y and Tran, Phuoc T and Madan, Ravi A},
  title = {National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {34},
  pages = {3672--3683},
  doi = {10.1200/jco-25-01693}
}
Kostenlos starten →